NASDAQ: GDTCCytomed Therapeutics Ltd Stock
$0.83-0.01 (-1.19%)
Updated Nov 13, 2026
GDTC Price
$0.83
Fair Value Price
-$0.19
Market Cap
$9.89M
52 Week Low
$0.68
52 Week High
$2.29
P/E
-3.53x
P/B
2.54x
P/S
48.84x
PEG
N/A
Dividend Yield
N/A
Revenue
$254.92k
Earnings
-$2.70M
Gross Margin
96.9%
Operating Margin
-1,070.15%
Profit Margin
-1,076.5%
Debt to Equity
0.33
Operating Cash Flow
-$3M
Beta
0.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GDTC Overview
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GDTC's potential to beat the market
- GDTC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GDTC
RankedUnranked of 450
RankedUnranked of 450
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.66 | A | |
| $955.47 | A | |
| $11.62 | A |
Be the first to know about important GDTC news, forecast changes, insider trades & much more!
GDTC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GDTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GDTC ($0.83) is overvalued by 532.18% relative to our estimate of its Fair Value price of -$0.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GDTC ($0.83) is not significantly undervalued (532.18%) relative to our estimate of its Fair Value price of -$0.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GDTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GDTC due diligence checks available for Premium users.
Valuation
GDTC fair value
Fair Value of GDTC stock based on Discounted Cash Flow (DCF)
Price
$0.83
Fair Value
-$0.19
Undervalued by
532.70%
GDTC ($0.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GDTC ($0.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GDTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GDTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.53x
Industry
18.58x
Market
41.11x
GDTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.54x
Industry
5.13x
GDTC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GDTC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GDTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GDTC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.4M
Liabilities
$1.2M
Debt to equity
0.33
GDTC's short-term assets ($2.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GDTC's short-term assets ($2.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GDTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
GDTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GDTC vs Biotech Stocks
Cytomed Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.